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Asymptomatic women who have received silicone injection for breast augmentation have a risk of underestimating breast cancer
by palpation, mammography, or breast sonography. Enhanced breast MRI is sensitive to display certain nonspeciﬁc enhanced
lesions or suspicious lesions. Such nonspeciﬁc MRI-detected lesions could be managed by American College Radiology BI-RADS
lexicon and selectively with MRI-guided techniques biopsy to prevent unnecessary surgery.
1.Introduction
Liquid silicone injection was ﬁrst used for breast augmen-
tation during the 1950s and 1960s [1]. Although the US
Food and Drug Administration (FDA) has never approved
the use of silicone injection, it has been illicitly performed
by both physicians and nonphysicians in the United States,
Mexico, and Asia [2, 3]. In patients who have received direct
silicone injection, various silicone-induced breast diseases,
including local granulomatous reactions, mastitis, foreign
body reaction, ﬁbrosis, silicone migration, and autoimmune
reactions, are common [1–6]. These reactive changes might
induce hard, nodular breast masses or structural distortion
mimicking neoplasm in certain cases. The masses containing
silicone are often pathologically diagnosed as so-called
siliconegranulomasorsiliconomas,whicharediﬃculttodif-
ferentiatefrombreastcancerbyconventionalmammography
or sonography due to the generalized increased density of
ﬁbrosis and siliconoma.
Women who ﬁrst received these silicone injections are
now at the age when a high incidence of breast cancers
occurs. In asymptomatic patients with silicone injection,
however, breast tumor detection by mammography or
sonography is controversial in terms of accuracy. They are
thus facing the risk of misdiagnosis or delayed diagnosis.
A breast mass becomes insensitive by palpation and becomes
occult within a tensed to hardened breast. Enhanced mag-
netic resonance imaging (MRI) is believed to be an ideal
imaging modality for further evaluation, but no reports
exist concerning MRI ﬁndings in women with asymptomatic
silicone-injected breasts.
In this study, we reviewed our clinical data for enhanced
MRI of women with asymptomatic silicone-injected breasts
to analyze MRI ﬁndings and MRI-guided interventional
procedures.
2. Patients andMethods
We retrospectively reviewed 33 consecutive patients aged 37–
87 years (mean age, 59 years) with asymptomatic silicone-
injected breasts who underwent breast MRI from 2008 to
2010 at our hospital. The results of mammography and
breast sonography were inconclusive in all patients.
For further evaluation, the patients were scheduled to
undergo enhanced MRI of the breasts with a 1.5T (HDx
Twin; GE, Milwaukee, WI, USA) or 3T (Tim Trio; Siemens,
Erlangen, Germany) imager using a standard protocol and
dynamic enhancement technique. The imaging protocols
included axial T1-weighted imaging, axial and sagittal T2-
weighted short τ inversion recovery (STIR) pulse sequences2 The Scientiﬁc World Journal
with fat and water saturation, and axial dynamic enhanced
imaging on T1-weighted images with fat suppression
(Siemens 3D turbo-FLASH pulse sequence: TR = 4ms,TE=
1.68ms, ﬂip angle =20◦,ﬁ e l do fv i e w3 4× 34cm, postcon-
trast 8 cycles with 1min/cycle or GE 3D VIBRANT pulse
sequence: TR = 7.3ms, TE = 3.3ms, ﬂip angle = 10◦,ﬁ e l d
of view 34 × 34cm, postcontrast 4 cycles with 2min/cycle).
We routinely used axial images for dynamic enhancement
evaluation because we could compare the enhancement of
both breasts at the same time, as well as document the
distribution of the enhanced lesions, whether symmetric
or asymmetric. Dynamic enhancement was performed by a
bolus injection of 0.1mmoL/kg gadopentetate dimeglumine
(Magnevist; Bayer Schering Pharma, Berlin, Germany) via
an intravenous catheter preset at the cubital region. MRI
then continuously captured the kinetic enhancement of
both breasts for 8min. The postenhanced acquisition data
were reconstructed by maximum intensity projection and
subtraction images for evaluation.
The MRI examinations were reported by an experienced
radiologist (>10 years experience). The examination results
weresubdividedasfollows:normalwithoutenhancedlesions
(BI-RADS 1), suspicious benign enhanced lesions (BI-RADS
2 or 3), or suspicious malignant enhanced lesions (BI-RADS
4 or 5). The classiﬁcation was based on the morphology of
enhanced lesions according to the Breast Imaging Reporting
andDataSystem(BI-RADS)lexiconoftheAmericanCollege
of Radiology (ACR). Foci or nodules ≤5mm(Figure 1), or
multiple diﬀuse nonmass enhancements (Figure 2), either
unilateral or bilateral, were suspicious of benign proliferative
c h a n g e ss u c ha sa d e n o s i so rﬁ b r o c y s t i cb r e a s td i s e a s e .F o ra n
enhanced mass (>5mm), smooth outlines were considered
to be benign. Otherwise, MRI guidance procedures for
biopsy were essentially recommended when the masses
were lobulated or had an irregular outline or the nonmass
enhancements were focal, linear, ductal, segmental, regional,
o rh a dac l u m p e da p p e a r a n c e .
MRI guidance procedures were ﬁrst introduced at our
hospital in 2008. All the MRI guidance procedures were
performed by the same radiologist who is specialized in
breast imaging, including mammography, sonography, and
biopsy with stereotactic, sonographic, or MRI guidance
procedures. After obtaining informed consent from the
patients, MRI was performed by a 1.5T MRI machine
(HDx Twin; GE) with the patients in the prone position.
The biopsied breast was immobilized by compression with
a grid plate. After localization of the enhanced biopsy
target, MRI-guided, vacuum-assisted, 10-gauge core needle
biopsy (MRI-VAB) (Bard, Vacora, Covington, CA, USA),
or preoperative needle localization with an MRI-compatible
titanium hooked guide wire (Bard, USA) was performed for
histopathological evaluation.
3. Results
Among the 33 asymptomatic patients, 16 had enhanced
lesions, which were manifest as multiple enhanced foci in
eight (Figure 1), enhanced masses in ﬁve, bilateral diﬀuse
Figure 1:Axial3Dmaximalintensityprojectionofenhancedbreast
MRIwithfatsuppressionshowednumerousfociinbilateralbreasts.
Figure 2: Axial 3D maximal intensity projection of enhanced
breast MRI with fat suppression shows diﬀuse nonmass inﬁltrating
enhancement symmetrically in bilateral breast parenchyma.
non-mass enhancement in two (Figure 2), and segmental
nonmass enhancement in one.
The ﬁve patients who displayed enhanced masses and the
one with segmental nonmass enhancement were suggested
for MRI-guided biopsy. However, only four women agreed
to receive MRI-guided interventional procedures, which
included vacuum-assisted core needle biopsy in three and
preoperative needle localization in one (Table 1). The MRI
appearance of biopsied lesions was lobular masses in two
cases, and irregular mass and segmental nonmass enhance-
ment in one each. With regard to the MRI lexicon, two
irregularorlobularmasseswithenhancedintratumoralsepta
were suggestive of possible malignancies. The irregular mass
was diagnosed as invasive lobular cancer (Figure 3) and the
lobular mass as ﬁbroadenoma. Another lobular mass showed
benign features, including a smooth outline, homogeneous
mild enhancement, and a continuously increasing intensity
time curve. We decided to perform MRI-guided needle
localization for excision biopsy due to the proximity of the
lesion to the mammoplastic bag. The diagnosis turned out
to be ﬁbroadenoma (Figure 4). The segmental nonmass,
enhanced lesion was shown pathologically by MRI-VAB to
be adenosis (Figure 5). Among these four suspicious lesions,
three showed moderate or rapid enhancement, either withThe Scientiﬁc World Journal 3
Table 1: Summary of MRI-guided interventional procedures in four asymptomatic silicone-injected breasts.
Age
(yr) Right/left Clinical history MRI features Enhancement curve Procedure Biopsy diagnosis
87 Left Unknown-origin bone








discovered during staging of

















51 Right Left breast cancer after
mastectomy 3 years before 0.8cm lobular mass Continuously slowly
increasing curve Wire localization Fibroadenoma
Figure 3: Axial fat-suppressed postcontrast breast MRI shows a
3cm enhanced irregular mass with focal irregular (white arrow) in
the left breast under compression before MRI-guided biopsy. It was
diagnosed as ILC by the biopsy.
washout or a plateau curve. Only one case was found to
be cancerous. No cancer was discovered in the two women
who refused MRI-guided procedures during 2 and 3 years of
followup. Among the MRI-guided cases, three patients had a
clinical history relating to cancer. The clinical information,
MRI appearance, and dynamic enhancement patterns are
described in Table 1.
No malignancy was discovered in this series with at least
1-year followup. Overall, only one of the 33 asymptomatic
patients was histologically diagnosed with breast cancer, but
thisaccountedfor25percent(1/4patients)amongthosewho
received MRI-guided interventional procedures.
4. Discussion
Direct injection of liquid silicone has been used in the
past for breast augmentation. Silicone-related breast disease
frequentlyleadstohardortenderbreaststhatmakepalpating
breast masses diﬃcult. Most of the cancers in silicone-
injected breasts were discovered and evaluated because of
palpation.Aseriesof16womenwithlumpysilicone-injected
breasts underwent enhanced MRI, and eight lumps were
histologically diagnosed as invasive ductal carcinoma in
Figure 4: Sagittal postcontrast breast MRI of an augmented breast
with silicone injection and mammoplastic bag placement showed
a 0.8cm lobular mass beneath the augmented mammoplasty bag,
with placement of an MRI-compatible guide wire (white arrow) for
excision localization.
three patients, silicone-induced mastitis in two, foreign body
reaction in two, and silicone granuloma in one [7]. In
another series, ﬁve of six surgically proven breast cancers
were associated with palpable masses [8].
Even though no evidence exists of silicone injection
being related to the occurrence of breast cancer, the reactive
changes in breasts can lead to diﬃculty in diagnosing
breastcancerbyconventionalmammographyorsonography,
particularly at an early stage. Enhancement of breast lesions
secondary to contrast medium leakage into the interstitial
spaces of the lesions has resulted in MRI becoming the
best or most sensitive imaging modality for identifying the
lesions, despite the structural distortion in the parenchymal
background. Enhanced MRI is thus believed to be the
optimal technique for detecting lesions in diﬃcult cases with
silicone-injected breasts.
In patients with liquid silicone injection, mammography
usually demonstrates dense breast tissue with parenchymal
distortion and opacity secondary to foreign body reaction
or ﬁbrosis, as well as the presence of silicone deposits
randomly disseminated within the breasts, axillary regions,4 The Scientiﬁc World Journal
Figure 5: Axial postcontrast breast MRI in a patient who received
silicone injection and mammoplastic bag placement shows a seg-
mental enhanced lesion in left breast with a biopsy coaxial needle
(white arrow) placed nearby. The biopsy diagnosis was adenosis.
or elsewhere. The typical diﬀuse involvement of the breast
by silicone granulomas or ﬁbrosis can obscure coexisting
neoplasms [9]. Similarly, the strong reﬂection, refraction,
reverberation, and attenuation of sonographic beams by
an overwhelming presence of silicone-induced ﬁbrosis or
silicone granuloma can lead to diﬀuse acoustic shadowing,
which substantially hinders observation. Loss of deﬁnition
of the posterior parenchyma has been reported as a common
featurethatisassociatedwithsonography[9].Theusefulness
of these two conventional imaging examinations is thus
limited.
Enhanced MRI has been documented as a better modal-
ity for patients with liquid silicone injection [7, 8, 10].
The consecutive high-resolution tomographic imaging of
breast MRI resolves the superimposition of breast lesions
under a heterogenous mammographic background. With
the addition of the enhanced technique, fast MRI greatly
improves spatial and temporal resolution of imaging, thus
enabling detection of angiogenic breast lesions or evaluation
of lesion morphology and extension.
To standardize breast MRI reporting, the ACR estab-
lished the BI-RADS MRI lexicon in 1998 [11], particularly
for describing two major categories of morphology and
enhancement kinetics. Morphologically, lesions can be sepa-
rated into focus/foci (≤5mm), mass (>5mm), and nonmass
enhancements. A focus is an enhanced spot ≤5mm. As
a result of its small size, it cannot be well characterized
morphologically. Multiple foci may cause a spurious result
for analysis of the enhancement kinetic curve because of the
volume-averaging eﬀect with surrounding normal tissue in
the selected region of interest [11]. A focus is usually due
to a benign lesion, such as focal ﬁbrocystic change [12],
papilloma, small ﬁbroadenoma, or intramammary lymph
node, although, rarely, it may also represent focal ductal
carcinoma in situ (DCIS) or small invasive cancer [13].
A mass is a three-dimensional space-occupying lesion
and is characterized by shape (round, oval, lobulated, irreg-
ular), margin (smooth, irregular, spiculated), and internal
mass enhancement characteristics (homogeneous, heteroge-
neous, rim enhancement, dark internal septations, enhanc-
ing internal septations, and central enhancement).
Nonmass enhancement is characterized by distribution
pattern (focal, linear, ductal, segmental, regional, multiple
regions,anddiﬀuse).Whethertheenhancementdistribution
is symmetric or asymmetric between the breasts should also
be determined. Multiple regions of enhancement or diﬀuse
enhancements are more characteristic of benign proliferative
changes. Although multicentric carcinoma, such as intra-
ductal carcinoma or invasive lobular carcinoma (ILC), may
exhibit a similar appearance, these ﬁndings are nearly always
unilateral [13–15], which is why we did not encourage our
eight patients with symmetrical, numerous enhanced foci in
both breasts to undergo biopsy.
Among the various shapes, irregular shape is the high-
est interobserver agreement for cancer, and lobular shape
is suggestive for ﬁbroadenoma [16]. However, a lobular
mass without septations, a mass with enhancing septations,
or moderate-to-marked, heterogeneous mass enhancement,
with washout kinetics, is highly suggestive of malignancy
but not speciﬁc for certain types of cancer [17]. For our
two breast masses with features that were suggestive of
possible malignancy, the irregular mass and lobular mass
with enhanced intratumoral septa were diagnosed as cancer
and ﬁbroadenoma, respectively, by MRI-VAB.
Liberman et al. have concluded that biopsy is rarely
necessary for lesions smaller than 5mm because of their
low (3 percent) likelihood of cancer [12]. Nevertheless,
the management of a focal lesion should depend on other
ﬁndings in the same or opposite breast (such as symmetry)
and corresponding ﬁndings from mammography or ultra-
sound, as well as the risk status of the patient [13, 18].
Enhanced nonmass lesions are neither a mass nor a blood
vessel. The enhancement pattern is distinct from normal
surrounding breast parenchyma without space-occupying
eﬀects. Benign or malignant lesions could present as non-
mass-like enhancement, such as DCIS, ILC, mastopathic
changes (focal adenosis), ﬁbrocystic changes due to hor-
monal stimulation, or inﬂammatory changes [13, 18].
Breast tumor intensity time curves are supposed to
allow us to distinguish malignancy from benignity, based
on diﬀerent neoangiogenesis formations [19, 20]. Tumor
neoangiogenesis or vascular permeability disruption by
benign disease could induce contrast medium leakage into
the interstitial spaces. However, the quantitative results vary
depending on analysis methods and acquisition parameters.
In addition to the interpretation of early enhancement, the
late phases of dynamic enhancement curves with washout,
plateau, or persistent increases are often used in clinical
practice. Malignant tumors usually have rapid or strong
enhancement, and benign lesions mostly show slow contin-
uously increasing enhancement [21]. Unfortunately, benign
or malignant lesions may reveal overlapping morphologi-
cal features or dynamic enhanced patterns [22, 23]. The
sensitivity of enhanced MRI for breast cancer has been
reported as high (91 percent), but it has low speciﬁcity (37
percent)anddiagnosticaccuracy(58percent)[24].However,
with addition of the patterns of dynamic signal intensityThe Scientiﬁc World Journal 5
time curves, the diagnostic accuracy for cancer increases to
86 percent [24]. Unfortunately, this improvement cannot
guarantee the diagnosis of malignancy from other benign
angiogenic processes [24].
Due to the limited speciﬁcity of enhanced MRI, histo-
logical diagnosis by percutaneous core needle biopsy may
help to avoid unnecessary surgery on benign MRI-detected
lesions. MRI-guided core needle biopsy was ﬁrst introduced
in 1997 by Heywang-K¨ obrunner et al., who also documented
that a vacuum-assisted core needle has much better perfor-
mance for obtaining large tissue volumes and hence reduces
sampling error [25]. Many authors have recommended
second-look sonography for MRI-detected breast lesions
that are suspicious or highly suggestive of malignancy.
If a sonographic correlate for the MRI-detected lesion is
conﬁdently identiﬁed, biopsy is usually performed under
sonographic guidance [26]. In cases without sonographic
correlates or only vague sonographic ﬁndings, MRI-guided
biopsy needs to be considered [27]. However, we prefer to
use the same imaging modality that conﬁdentially revealed
the suspicious lesions as the guiding tool. In contrast
with our ﬁndings for silicone-injected breasts, subsequent
management with MRI-guided interventional procedures
for biopsy is indicated because of poor demonstration by
sonography.
A European multicenter study has reported no false-
negative results among 517 successful MRI-VAB procedures
[28]. The current results show that MRI-VAB is a reliable
method that can obviate unnecessary surgery. However,
MRI-VAB may not be feasible in some patients who cannot
tolerate the procedures for various reasons, such as insuf-
ﬁcient breast thickness or target lesions close to the chest
wall. In addition, in our biopsy case 4, the target lesion
was located beneath the mammoplastic bag, which resulted
in us performing preoperative wire localization rather than
MRI-VAB.Nevertheless,thesetwoproceduresaretechnically
similar and familiar to the performer.
5. Conclusions
From our small number of cases, we could not calculate the
accuracy of MRI examinations or MRI-guided procedures
for cancer diagnosis due to a lack of gold standard surgery.
We understood that enhanced breast MRI would display
certain enhanced lesions in such diﬃcult cases; however, we
selected suspicious lesions that required biopsy based on the
ACR BI-RADS lexicon. In conclusion, enhanced breast MRI
examination with MRI-guided interventional procedures is




breast implants—types, complications, and adjacent breast
pathology,” Current Problems in Diagnostic Radiology, vol. 22,
no. 2, pp. 41–86, 1993.
[2] Collagen and liquid silicone injections. FDA Backgrounder.
BG 91-5.1, 1991.
[3] B. G. Steinbach, N. S. Hardt, P. L. Abbitt, L. Lanier, and
H. H. Caﬀee, “Breast implants, common complications, and
concurrent breast disease,” Radiographics,v o l .1 3 ,n o .1 ,p p .
95–118, 1993.
[4] K. Boo-Chai, “The complications of augmentation mamma-
plasty by silicone injection,” British Journal of Plastic Surgery,
vol. 22, no. 3-4, pp. 281–285, 1969.
[5] E. H. Kopf, C. A. Vinnik, and J. J. D. J. Bongiovi and-
Dombrowski, “Complications of silicone injections,” Rocky
Mountain Medical Journal, vol. 73, no. 2, pp. 77–80, 1976.
[6] W. D. Travis, K. Balogh, and J. L. Abraham, “Silicone
granulomas: report of three cases and review of the literature,”
Human Pathology, vol. 16, no. 1, pp. 19–27, 1985.
[7] Y. C. Cheung, M. Y. Su, S. H. Ng, K. F. Lee, S. C. Chen, and
Y. F. Lo, “Lumpy silicone-injected breasts: enhanced MRI and
microscopic correlation,” Clinical Imaging,v o l .2 6 ,n o .6 ,p p .
397–404, 2002.
[8] J. H. Youk, E. J. Son, E. K. Kim et al., “Diagnosis of breast
cancer at dynamic MRI in patients with breast augmentation
by paraﬃn or silicone injection,” Clinical Radiology, vol. 64,
no. 12, pp. 1175–1180, 2009.
[9] A. J. Leibman and R. Sybers, “Mammographic and sono-
graphic ﬁndings after silicone injection,” Annals of Plastic
Surgery, vol. 33, no. 4, pp. 412–414, 1994.
[10] H. L. Peng, C. C. Wu, W. M. Choi, M. S. Hui, T. N. Lu, and L.
K. Chen, “Breast cancer detection using magnetic resonance
imaging in breasts injected with liquid silicone,” Plastic and
Reconstructive Surgery, vol. 104, no. 7, pp. 2116–2120, 1999.
[11] American College of Radiology, Breast Imaging Reporting
and Data System (BI-RADS), American College of Radiology,
Reston, Va, USA, 4th edition, 2003.
[12] L. Liberman, G. Mason, E. A. Morris, and D. D. Dershaw,
“Does size matter? Positive predictive value of MRI-detected
breast lesions as a function of lesion size,” American Journal of
Roentgenology, vol. 186, no. 2, pp. 426–430, 2006.
[13] C. Kuhl, “The current status of breast MR imaging. Part I.
Choice of technique, image interpretation, diagnostic accu-
racy, and transfer to clinical practice,” Radiology, vol. 244, no.
2, pp. 356–378, 2007.
[14] M. A. A. J. Van Den Bosch, B. L. Daniel, M. N. Mariano et
al., “Magnetic resonance imaging characteristics of ﬁbrocystic
change ofthebreast,” InvestigativeRadiology,vol.40,no.7,pp.
436–441, 2005.
[15] A. Qayyum, R. L. Birdwell, B. L. Daniel et al., “MR imaging
features of inﬁltrating lobular carcinoma of the breast:
histopathologic correlation,” American Journal of Roentgenol-
ogy, vol. 178, no. 5, pp. 1227–1232, 2002.
[16] D. M. Ikeda, N. M. Hylton, K. Kinkel et al., “Develop-
ment, standardization, and testing of a lexicon for reporting
contrast-enhanced breast magnetic resonance imaging stud-
ies,” Journal of Magnetic Resonance Imaging,v o l .1 3 ,n o .6 ,p p .
889–895, 2001.
[ 1 7 ]K .J .M a c u r a ,R .O u w e r k e r k ,M .A .J a c o b s ,a n dD .A .
Bluemke, “Patterns of enhancement on breast MR images:
interpretationandimagingpitfalls,” Radiographics,vol.26,no.
6, pp. 1719–1734, 2006.
[18] C. K. Kuhl, “Concepts for diﬀerential diagnosis in breast
MR imaging,” Magnetic Resonance Imaging Clinics of North
America, vol. 14, no. 3, pp. 305–328, 2006.
[19] M. V. Knopp, E. Weiss, H. P. Sinn et al., “Pathophysiologic
basis of contrast enhancement in breast tumors,” Journal of
Magnetic Resonance Imaging, vol. 10, no. 3, pp. 260–266, 1999.
[20] C. K. Kuhl, “Science to practice: why do purely intraductal
cancers enhance on breast MR images?” Radiology, vol. 253,
no. 2, pp. 281–283, 2009.6 The Scientiﬁc World Journal
[21] C.Boetes,J.O.Barentsz,R.D.Musetal.,“MRcharacterization
of suspicious breast lesions with a gadolinium- enhanced
TurboFLASH subtraction technique,” Radiology, vol. 193, no.
3, pp. 777–781, 1994.
[ 2 2 ]S .H .H e y w a n g ,A .W o l f ,E .P r u s s ,T .H i l b e r t z ,W .E i e r m a n n ,
and W. Permanetter, “MR imaging of the breast with Gd-
DTPA: use and limitations,” Radiology, vol. 171, no. 1, pp. 95–
103, 1989.
[23] S. G. Orel, M. D. Schnall, V. A. LiVolsi, and R. H. Troupin,
“Suspicious breast lesions: MR imaging with radiologic-
pathologic correlation,” Radiology, vol. 190, no. 2, pp. 485–
493, 1994.
[24] C. K. Kuhl, P. Mielcareck, S. Klaschik et al., “Dynamic breast
MR imaging: are signal intensity time course data useful for
diﬀerential diagnosis of enhancing lesions?” Radiology, vol.
211, no. 1, pp. 101–110, 1999.
[25] S. H. Heywang-K¨ obrunner, A. Heinig, U. Schauml¨ oﬀel et al.,
“MR-guided percutaneous excisional and incisional biopsy of
breast lesions,” European Radiology, vol. 9, no. 8, pp. 1656–
1665, 1999.
[26] W. B. Demartini, P. R. Eby, S. Peacock, and C. D. Lehman,
“Utility of targeted sonography for breast lesions that were
suspicious on MRI,” American Journal of Roentgenology, vol.
192, no. 4, pp. 1128–1134, 2009.
[27] S. H. Heywang-K¨ obrunner, R. Sinnatamby, A. Lebeau, A.
Lebrecht, P. D. Britton, and I. Schreer, “Interdisciplinary
consensus on the uses and technique of MR-guided vacuum-
assisted breast biopsy (VAB): results of a European consensus
meeting,” European Journal of Radiology,v o l .7 2 ,n o .2 ,p p .
289–294, 2009.
[28] C. Perlet, S. H. Heywang-Kobrunner, A. Heinig et al., “Mag-
neticresonance-guided,vacuum-assistedbreastbiopsy:results
fromaEuropeanmulticenterstudyof538lesions,”Cancer,vol.
106, no. 5, pp. 982–990, 2006.